The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

Port fuel injection (PFI) was a major milestone in the early '80s. The integration of PFI rapidly changed the way fuel was delivered by increasing fuel economy and improving engine performance. Even ...

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the ...

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections. The drug, called enlicitide, slashes levels ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Amgen AMGN reported third-quarter 2025 adjusted earnings of $5.64 per share, which beat the Zacks Consensus Estimate of $5.00 per share. Earnings rose 1% year over year as higher revenues were ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...

Councilman Ben Rutherford shares the amendments to Resolution 79 during Thursday’s Marietta City Council meeting at the Armory. (Photo by Gwen Sour) MARIETTA — Marietta City Council on Thursday ...

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...